Table 1. Demographic and clinical characteristics of ankylosing spondylitis patients and control subjects.
| Mean±SD | Median | Min-Max | Mean±SD | Median | Min-Max | P | |
|---|---|---|---|---|---|---|---|
| Age (year) | 40.1±10.8 | 41.2±9.3 | 0.61 | ||||
| Body mass index (kg/m2) | 25.8±2.4 | 25.6±1.8 | 0.9 | ||||
| Disease duration (year) | 10.6±4.2 | ||||||
| BASDAI | 4.0±2.8 | 2.2-6.7 | |||||
| ESR (mm/h) (CI) | 13.8±9-2 | 4.8±4-7 | 0.041 | ||||
| Triglyceride (mg/dL) | 112.8 | 97-155 | 108.4 | 85-137 | 0.56 | ||
| LDL-C (mg/dL) | 154.8 | 112-168 | 132.6 | 108-175 | 0.6 | ||
| C-reactive protein (mg/L) (CI) | 16.2±4.7 | 6.5-38.9 | 1.6±0.3 | 1.0-2.5 | 0.03 | ||
| Glycemia (mg/dL) | 88.2±9.4 | 78-96 | 91±6.9 | 83-95 | 0.4 | ||
| NSAIDS | 41 | ||||||
| Biologic agents | 30 | ||||||
| AS: Ankylosing spondylitis; SD: Standard deviation; Min: Minimum; Max: Maximum; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ESR: Erythrocyte sedimentation rate; CI: Confidence interval; LDL-C: Low-density lipoprotein cholesterol; NSAIDs: Nonsteroidal antiinflammatory drugs. | |||||||